

ASX ANNOUNCEMENT

KEY MIDKINE INHIBITOR PATENT GRANTED IN EUROPE

- **European patent for treating autoimmune disorders using midkine inhibitors granted**
- **Relates to novel mechanism of action boosting regulatory T cells**
- **USA and Japanese patents already granted in the family**

SYDNEY, Tuesday, 1 December 2015: Cellmid Limited (ASX: CDY) advises that the European Patent Office (EPO) granted Cellmid's patent application 06832616.4 "Method for treatment or prevention of diseases associated with a functional disorder of regulatory T cells".

European patent application 06832616.4 is a member of a key patent family in Cellmid's midkine (MK) inhibitor patent portfolio and includes MK antibodies, antisense RNA and dsRNA against MK. Its grant adds an important layer of intellectual property protection to Cellmid's MK inhibitor programmes. Importantly, it forms the basis for the commercial development of Cellmid's MK antibodies in autoimmune disease indications.

EPA 06832616.4 covers the use of MK inhibitors in diseases where the increase of regulatory T cells (Tregs) may be beneficial for treatment, such as multiple sclerosis.

Tregs are important controllers of autoimmune responses; when Treg numbers are too low, the body's immune system can attack its own tissues, leaving subjects vulnerable to autoimmune diseases. Increasing the Treg numbers can mitigate such autoimmune attack.

Published studies show that MK suppresses Treg numbers, but Treg numbers can be boosted by the use of MK antibodies. In animal models of autoimmunity, inhibiting MK using Cellmid's MK antibodies alleviated disease.

This is the third member of the patent family; the US patent was granted in 2012 and the Japanese patent was granted in 2013. The patents in this family expire in 2027.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programmes in multiple disease indications. The Company is developing innovative novel therapies and diagnostic tests for cancer and inflammatory diseases as well as OTC treatments for hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Advangen Limited and hair growth products

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, China and Taiwan. Concurrently, Advangen has been studying midkine, a growth factor, in hair loss models utilising its anti-apoptotic effects. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is highly anti-apoptotic protecting cells from dying. It is this mechanism of action that is thought to be responsible for midkine's ability to regenerate hair growth in various models of the condition.